Main Content

“2020health is an important and thoughtful contributor to the health debate”

Dr Sarah Wollaston MP, Chairman, Health Select Committee

 
 

How can NICE add value to the NHS over the next 10 years?

Jul 15. till Jul 15.

Invitation Only Event

Hosted by
John Penrose MP

With guest speaker
Professor David Haslam, Chairman, NICE

Date
July 15, 20142014-07-15T01:00:00 - July 15, 2014 2014-07-15T02:30:00
Time
1:00 PM 2014-07-15T01:00:00 - 2:30 PM 2014-07-15T02:30:00
Location
Portcullis House, Westminster

The purpose of NICE is to improve the quality and productivity of healthcare, public health and social care. The stated aim is to be the principal UK resource for evidence-based practice, commissioning and local decision-making, in health and social care, including practical support to help put our recommendations into practice.

Originally established in April 1999 to set clinical standards, their role was extended in 2005 to include advice on effective and cost effective public health practice, and again in 2008 when they were asked to produce quality standards and to review the clinical and health improvement indicator set in the primary care Quality and Outcomes Framework. At the same time, their existing technology evaluation programme was extended and they added more capacity to evaluate medical devices and diagnostics. NHS Evidence, a resource for decision-makers in health and social care was launched in 2009.

In the current NICE business plan, they state: We will make sure that the way we work contributes to the long term health of the UK life sciences industries, through fair and objective evaluation of their products and by stimulating the NHS to adopt effective and cost effective products and services.

The Institute’s work is internationally respected for the quality of its recommendations on a wide range of medical issues and plays a major and growing role in informing and educating doctors, other healthcare professionals and policymakers. Only a small proportion now of NICE’s work relates to advice on drugs, though this is often what hits the press.

It could be argued however that in the light of the NHS budget cap in the 2014 PPRS agreement that there is now no need for NICE to give a medical opinion on whether a drug should be available for any particular use or not. The MHRA decides for what uses drugs are safe and effective. Added to this, genomics is showing us that the most effective way now to tackle cancer is to identify the genomic signature – should this mean that all guidance for the treatment of cancer be reviewed, and extra time and money be directed to bolstering genetic counselling and diagnostics?